Cargando…

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway

BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that exhibit multiple extraglycemic effects. However, there are conflicting results regarding the effects of SGLT2 inhibition on energy expenditure and thermogenesis. Therefore, we investigated the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji-Yeon, Lee, Minyoung, Lee, Ji Young, Bae, Jaehyun, Shin, Eugene, Lee, Yong-ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640151/ https://www.ncbi.nlm.nih.gov/pubmed/33611885 http://dx.doi.org/10.4093/dmj.2020.0187

Ejemplares similares

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
por: Han, Eugene, et al.
Publicado: (2020)

The effects of the voglibose on non-alcoholic fatty liver disease in mice model
por: Bae, Jaehyun, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
por: Lee, Minyoung, et al.
Publicado: (2020)

Gynostemma Pentaphyllum Extract Ameliorates High-Fat Diet-Induced Obesity in C57BL/6N Mice by Upregulating SIRT1
por: Lee, Hyun Sook, et al.
Publicado: (2019)

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
por: Miyauchi, Masaaki, et al.
Publicado: (2017)

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
por: Salim, Hotimah Masdan, et al.
Publicado: (2016)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

Chrysanthemum morifolium Flower Extract Ameliorates Obesity-Induced Inflammation and Increases the Muscle Mitochondria Content and AMPK/SIRT1 Activities in Obese Rats
por: Lee, Yoonjin, et al.
Publicado: (2021)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
por: Min, Kyung-Wan, et al.
Publicado: (2017)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Vitamin D Ameliorates Fat Accumulation with AMPK/SIRT1 Activity in C2C12 Skeletal Muscle Cells
por: Chang, Eugene, et al.
Publicado: (2019)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Abeliophyllum distichum Ameliorates High-Fat Diet-Induced Obesity in C57BL/6J Mice by Upregulating the AMPK Pathway
por: Eom, Ji, et al.
Publicado: (2020)

Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
por: Lee, Sejeong, et al.
Publicado: (2023)

Zerumbone ameliorates high-fat diet-induced adiposity by restoring AMPK-regulated lipogenesis and microRNA-146b/SIRT1-mediated adipogenesis
por: Ahn, Jiyun, et al.
Publicado: (2017)

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease
por: Miyake, Teruki, et al.
Publicado: (2018)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
por: Okuma, Hideyuki, et al.
Publicado: (2021)

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report
por: Okada, Shuichi, et al.
Publicado: (2014)

Anatomic fat depots and cardiovascular risk: a focus on the leg fat using nationwide surveys (KNHANES 2008–2011)
por: Han, Eugene, et al.
Publicado: (2017)

Citrus Peel Extract Ameliorates High-Fat Diet-Induced NAFLD via Activation of AMPK Signaling
por: Lee, Geum-Hwa, et al.
Publicado: (2020)

Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using (11)C‐MDG
por: Mitsuoka, Keisuke, et al.
Publicado: (2016)

CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes
por: Chang, Eugene, et al.
Publicado: (2018)

Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus
por: Seok, Hannah, et al.
Publicado: (2019)

Astaxanthin Ameliorates high-fat diet-induced cardiac damage and fibrosis by upregulating and activating SIRT1
por: Shatoor, Abdullah S., et al.
Publicado: (2021)

D-allulose ameliorates adiposity through the AMPK-SIRT1-PGC-1α pathway in HFD-induced SD rats
por: Lee, Geum-Hwa, et al.
Publicado: (2021)

Proteinuria Is Associated with Carotid Artery Atherosclerosis in Non-Albuminuric Type 2 Diabetes: A Cross-Sectional Study
por: Bae, Jaehyun, et al.
Publicado: (2020)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
por: Kim, Youngsook, et al.
Publicado: (2022)

Mangiferin Ameliorates Obesity-Associated Inflammation and Autophagy in High-Fat-Diet-Fed Mice: In Silico and In Vivo Approaches
por: Noh, Ji-Won, et al.
Publicado: (2022)

Protective Effect of Delta-Like 1 Homolog Against Muscular Atrophy in a Mouse Model
por: Lee, Ji Young, et al.
Publicado: (2022)

Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet
por: Liou, Chian-Jiun, et al.
Publicado: (2019)

Mulberry (Morus alba L.) Fruit Extract Ameliorates Inflammation via Regulating MicroRNA-21/132/143 Expression and Increases the Skeletal Muscle Mitochondrial Content and AMPK/SIRT Activities
por: Jung, Sunyoon, et al.
Publicado: (2021)

SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model
por: Tahara, Atsuo, et al.
Publicado: (2019)

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet
por: Takagi, Susumu, et al.
Publicado: (2018)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2018)

Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2020)

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
por: Han, Kyung‐Ah, et al.
Publicado: (2018)

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
por: Kim, So Ra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4bm5tj9cvtibhjuiqu8m9s0g2m